Molecular Templates announces FDA acceptance of IND application for MT-511
Molecular Templates announced the FDA has accepted its Investigational New Drug application for MT-5111, an ETB targeting HER2. MTEM expects to start dosing in a Phase I study in relapsed/refractory patients with HER2-positive solid tumors in 3Q19. April 22, 2019